MCID: CHR563
MIFTS: 53

Chronic Eosinophilic Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Eosinophilic Leukemia

MalaCards integrated aliases for Chronic Eosinophilic Leukemia:

Name: Chronic Eosinophilic Leukemia 12 60 38 15 74
Pdgfra-Associated Chronic Eosinophilic Leukemia 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0080367
KEGG 38 H01590
NCIt 51 C4563
ICD10 34 D47.5
ICD10 via Orphanet 35 D47.5
UMLS via Orphanet 75 C0346421
Orphanet 60 ORPHA168940

Summaries for Chronic Eosinophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.

MalaCards based summary : Chronic Eosinophilic Leukemia, also known as pdgfra-associated chronic eosinophilic leukemia, is related to pdgfra-associated chronic eosinophilic leukemia and myeloproliferative neoplasm. An important gene associated with Chronic Eosinophilic Leukemia is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Chronic eosinophilic leukemia is a form of cancer in which too many eosinophils are found in the bone... more...

Related Diseases for Chronic Eosinophilic Leukemia

Diseases related to Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 pdgfra-associated chronic eosinophilic leukemia 34.6 PDGFRA FIP1L1
2 myeloproliferative neoplasm 30.7 ABL1 FGFR1 FIP1L1 JAK2 KIT PDGFRA
3 mastocytosis 30.3 FIP1L1 KIT PDGFRA PDGFRB
4 loeffler endocarditis 30.2 FIP1L1 PDGFRA
5 endomyocardial fibrosis 30.2 FIP1L1 PDGFRA
6 hypereosinophilic syndrome 30.0 ABL1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
7 leukemia 29.9 ABL1 FLT3 JAK2 KIT WT1
8 hypereosinophilic syndrome, idiopathic 29.6 FIP1L1 KIT PDGFRA PDGFRB WT1
9 systemic mastocytosis 29.4 FGFR1 FIP1L1 JAK2 KIT PDGFRA PDGFRB
10 myelofibrosis 29.1 FLT3 JAK2 KIT
11 acute leukemia 28.7 FLT3 JAK2 KIT WT1
12 myeloid leukemia 28.6 ABL1 FLT3 JAK2 KIT WT1
13 leukemia, acute myeloid 28.3 ABL1 FLT3 JAK2 KIT WT1
14 pdgfrb-associated chronic eosinophilic leukemia 12.6
15 reticular perineurioma 10.3 KIT PDGFRA
16 gastric leiomyosarcoma 10.3 KIT PDGFRA
17 conventional fibrosarcoma 10.3 KIT PDGFRA
18 endometrial small cell carcinoma 10.3 KIT PDGFRA
19 lung adenoid cystic carcinoma 10.3 KIT PDGFRA
20 pulmonary vein stenosis 10.3 KIT PDGFRA
21 cellular neurofibroma 10.2 ABL1 PDGFRB
22 carney triad 10.2 KIT PDGFRA
23 undifferentiated pleomorphic sarcoma 10.2 KIT PDGFRA
24 corneal dystrophy, subepithelial mucinous 10.2 FIP1L1 PDGFRA PDGFRB
25 neurofibromatosis, type i 10.2 KIT PDGFRA
26 sm-ahnmd 10.2 FIP1L1 KIT PDGFRA
27 spinal chordoma 10.2 PDGFRA PDGFRB
28 desmoid tumor 10.1 KIT PDGFRA PDGFRB
29 fibrosarcoma of bone 10.1 KIT PDGFRA PDGFRB
30 dermatofibrosarcoma protuberans 10.1 KIT PDGFRA PDGFRB
31 testicular gonadoblastoma 10.1 KIT WT1
32 gonadoblastoma 10.1 KIT WT1
33 peritoneal benign neoplasm 10.1 KIT WT1
34 mesenchymal cell neoplasm 10.1 KIT PDGFRA TPM3
35 diffuse peritoneal leiomyomatosis 10.1 KIT WT1
36 cystic nephroma 10.1 KIT WT1
37 budd-chiari syndrome 10.1 PDGFRA JAK2 FIP1L1
38 mixed germ cell-sex cord neoplasm 10.0 KIT WT1
39 spindle cell liposarcoma 10.0 KIT WT1
40 myelodysplastic myeloproliferative cancer 10.0 ABL1 JAK2
41 primary hypereosinophilic syndrome 10.0 FGFR1 FIP1L1 PDGFRA PDGFRB
42 congenital mesoblastic nephroma 10.0 KIT WT1
43 acute myeloblastic leukemia with maturation 10.0 FLT3 KIT
44 prostatic acinar adenocarcinoma 10.0 KIT WT1
45 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.0 FLT3 KIT
46 lymphoma 10.0
47 lymphoblastic leukemia, acute, with lymphomatous features 9.9 ABL1 FGFR1 JAK2
48 uterine sarcoma 9.9 KIT PDGFRB WT1
49 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9 FLT3 KIT
50 subacute myeloid leukemia 9.9 FLT3 JAK2

Graphical network of the top 20 diseases related to Chronic Eosinophilic Leukemia:



Diseases related to Chronic Eosinophilic Leukemia

Symptoms & Phenotypes for Chronic Eosinophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

27 (show all 39)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.29 FLT3 PDGFRA
2 Decreased viability GR00221-A-1 10.29 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 10.29 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.29 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.29 FLT3 PDGFRA PDGFRB
6 Decreased viability GR00301-A 10.29 KIT
7 Decreased viability GR00342-S-1 10.29 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 10.29 ABL1
9 Decreased viability GR00342-S-3 10.29 ABL1
10 Decreased viability GR00402-S-2 10.29 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
11 Decreased substrate adherent cell growth GR00193-A-1 10.1 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 10.1 ABL1 JAK2 KIT
13 Decreased substrate adherent cell growth GR00193-A-3 10.1 JAK2
14 Decreased substrate adherent cell growth GR00193-A-4 10.1 ABL1 KIT FGFR1 FLT3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.81 ABL1 WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.81 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.81 ABL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.81 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.81 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.81 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.81 KIT WT1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.81 ABL1 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.81 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.81 WT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.81 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.81 ABL1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.81 ABL1 KIT WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.81 WT1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.81 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.81 ABL1 WT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.81 ABL1 WT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.81 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.81 ABL1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.81 ABL1 KIT WT1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.81 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.81 KIT
37 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.62 ABL1 FGFR1 FLT3 PDGFRB
38 Condensed cis-Golgi GR00365-A 9.54 FGFR1 FLT3 PDGFRA
39 Increased cell viability after pRB stimulation GR00230-A-1 9.13 ABL1 KIT PDGFRB

MGI Mouse Phenotypes related to Chronic Eosinophilic Leukemia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.2 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
2 growth/size/body region MP:0005378 10.15 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
3 hematopoietic system MP:0005397 10.13 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
4 endocrine/exocrine gland MP:0005379 10.11 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
5 immune system MP:0005387 10.11 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
6 mortality/aging MP:0010768 10.1 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
7 embryo MP:0005380 10.07 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
8 craniofacial MP:0005382 10.01 ABL1 CDK5RAP2 FGFR1 KIT PDGFRA PDGFRB
9 integument MP:0010771 9.91 CDK5RAP2 FGFR1 JAK2 KIT PDGFRA PDGFRB
10 muscle MP:0005369 9.91 ABL1 FGFR1 KIT PDGFRA PDGFRB TPM3
11 neoplasm MP:0002006 9.8 CDK5RAP2 FLT3 JAK2 KIT PDGFRA WT1
12 no phenotypic analysis MP:0003012 9.73 FGFR1 FLT3 KIT PDGFRA TPM3 WT1
13 normal MP:0002873 9.7 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
14 reproductive system MP:0005389 9.5 CDK5RAP2 FGFR1 JAK2 KIT PDGFRA PDGFRB
15 skeleton MP:0005390 9.23 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT

Drugs & Therapeutics for Chronic Eosinophilic Leukemia

Drugs for Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
4
Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
5 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
18
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
19
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
20
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
21
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
22
Aldesleukin Approved Phase 3,Phase 2 85898-30-2, 110942-02-4
23
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
24
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
28
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
29
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
30
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
31
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
32
Thioguanine Approved Phase 3 154-42-7 2723601
33
Acyclovir Approved Phase 3 59277-89-3 2022
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
35
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
36
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
37
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
38
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Not Applicable 1177-87-3
40
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-02-2 5743
41
midostaurin Approved, Investigational Phase 3 120685-11-2 9829523 104937
42
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
43
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
44
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 1 123318-82-1 119182
45
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
46
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 460612 4053
47
Calcium Approved, Nutraceutical Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
48
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Staurosporine Experimental Phase 3 62996-74-1

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 prednisone
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
16 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
17 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
18 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
19 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
20 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
21 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
23 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
24 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
25 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
26 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
27 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
28 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
29 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
30 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
31 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
32 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
33 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
34 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
35 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
36 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
37 Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Not yet recruiting NCT03801434 Phase 2 Ruxolitinib
38 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Active, not recruiting NCT02071901 Phase 2 eltrombopag olamine
39 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
40 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
41 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
42 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
43 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
44 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
45 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
46 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
47 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
48 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
49 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
50 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide

Search NIH Clinical Center for Chronic Eosinophilic Leukemia

Genetic Tests for Chronic Eosinophilic Leukemia

Anatomical Context for Chronic Eosinophilic Leukemia

MalaCards organs/tissues related to Chronic Eosinophilic Leukemia:

42
Myeloid, Bone, Bone Marrow, Liver, Eye, T Cells, Kidney

Publications for Chronic Eosinophilic Leukemia

Articles related to Chronic Eosinophilic Leukemia:

(show top 50) (show all 107)
# Title Authors Year
1
A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31). ( 30697976 )
2019
2
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRI+ kinase inhibitor for PDGFRI+ driving chronic eosinophilic leukemia. ( 29544149 )
2018
3
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). ( 29384404 )
2018
4
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
5
Integration of a bacterial gene sequence into a chronic eosinophilic leukemia patient's genome as part of a fusion gene linker. ( 28593047 )
2017
6
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
7
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. ( 28651427 )
2017
8
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in china. ( 27120808 )
2016
9
Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. ( 27267816 )
2016
10
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. ( 27458550 )
2016
11
Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations. ( 27512192 )
2016
12
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
13
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement. ( 27722133 )
2016
14
Chronic eosinophilic leukemia with a FIP1L1-PDGFRA rearrangement: Two case reports and a review of Korean cases. ( 25830134 )
2015
15
Delayed diagnosis leading to accelerated phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. ( 26503642 )
2015
16
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene. ( 24975316 )
2015
17
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. ( 26492057 )
2015
18
Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. ( 25923837 )
2015
19
Murine models of eosinophilic leukemia: a model of FIP1L1-PDGFRI+ initiated chronic eosinophilic leukemia/systemic mastocytosis. ( 24986627 )
2014
20
Chronic eosinophilic leukemia with monosomy 8 in a five-year-old girl: a rare case. ( 25818969 )
2014
21
Chronic eosinophilic leukemia: a rare cause of hypereosinophilic syndrome. ( 25065049 )
2014
22
FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India. ( 24764730 )
2014
23
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. ( 25015329 )
2014
24
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRI+: roles of Mcl-1 and I^-catenin. ( 24472312 )
2014
25
Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified. ( 24449233 )
2014
26
Chronic eosinophilic leukemia with FIP1L1-PDGFRA. ( 23550302 )
2013
27
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. ( 24057647 )
2013
28
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. ( 23630205 )
2013
29
Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. ( 23621172 )
2013
30
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. ( 23982058 )
2013
31
Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. ( 24224106 )
2013
32
Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. ( 22449623 )
2012
33
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. ( 21818111 )
2012
34
Chronic eosinophilic leukemia presenting with mouth and penile ulcers. ( 22681908 )
2012
35
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. ( 22899477 )
2012
36
An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report. ( 21881824 )
2012
37
Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target? ( 22288769 )
2012
38
Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. ( 22473587 )
2012
39
Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. ( 21841337 )
2011
40
Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. ( 21302907 )
2011
41
Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. ( 21072821 )
2011
42
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. ( 21281241 )
2011
43
Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. ( 20609486 )
2011
44
Chronic eosinophilic leukemia with FIP1L1-PDGFRA transcripts after occupational and therapeutic exposure to radiation. ( 22184538 )
2011
45
A chronic eosinophilic leukemia patient presenting with blurred vision. ( 27264376 )
2011
46
Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. ( 20558942 )
2010
47
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. ( 20726440 )
2010
48
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. ( 19118067 )
2009
49
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. ( 19761433 )
2009
50
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. ( 19210352 )
2009

Variations for Chronic Eosinophilic Leukemia

Expression for Chronic Eosinophilic Leukemia

Search GEO for disease gene expression data for Chronic Eosinophilic Leukemia.

Pathways for Chronic Eosinophilic Leukemia

Pathways related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
2
Show member pathways
13.34 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
3
Show member pathways
13.3 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB
4
Show member pathways
13.22 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
5
Show member pathways
13.15 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
6
Show member pathways
13.14 FGFR1 FLT3 KIT PDGFRA PDGFRB
7
Show member pathways
13.12 FGFR1 JAK2 KIT PDGFRA PDGFRB
8
Show member pathways
13.09 FGFR1 FLT3 KIT PDGFRA PDGFRB
9
Show member pathways
12.87 FGFR1 JAK2 KIT PDGFRA PDGFRB
10
Show member pathways
12.81 FGFR1 FLT3 KIT PDGFRA PDGFRB
11
Show member pathways
12.75 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
12
Show member pathways
12.69 FGFR1 JAK2 PDGFRA PDGFRB
13
Show member pathways
12.56 FGFR1 KIT PDGFRA PDGFRB
14 12.56 FGFR1 FLT3 KIT PDGFRA PDGFRB
15
Show member pathways
12.55 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
16
Show member pathways
12.52 FGFR1 JAK2 PDGFRA PDGFRB
17
Show member pathways
12.44 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
18 12.28 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
19
Show member pathways
12.22 ABL1 JAK2 PDGFRA PDGFRB
20
Show member pathways
12.2 FGFR1 FLT3 KIT PDGFRA PDGFRB
21
Show member pathways
12.06 ABL1 FGFR1 KIT PDGFRA PDGFRB
22 11.97 FGFR1 PDGFRA PDGFRB
23 11.71 FGFR1 PDGFRA PDGFRB
24
Show member pathways
11.62 FGFR1 FLT3 KIT PDGFRB
25
Show member pathways
11.56 ABL1 KIT PDGFRA PDGFRB
26 11.37 FGFR1 FLT3 KIT PDGFRA PDGFRB
27 11.35 FGFR1 PDGFRA PDGFRB
28 11.34 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
29 11.29 FGFR1 PDGFRA PDGFRB
30 11.23 FGFR1 JAK2 PDGFRA PDGFRB
31 10.99 PDGFRA PDGFRB
32 10.84 FGFR1 FLT3 KIT PDGFRA PDGFRB
33 10.75 PDGFRA PDGFRB

GO Terms for Chronic Eosinophilic Leukemia

Cellular components related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.65 ABL1 CDK5RAP2 FGFR1 FLT3 JAK2 KIT
2 intrinsic component of plasma membrane GO:0031226 9.16 PDGFRA PDGFRB
3 receptor complex GO:0043235 9.02 FGFR1 FLT3 KIT PDGFRA PDGFRB

Biological processes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.92 JAK2 KIT PDGFRA PDGFRB
2 positive regulation of protein kinase B signaling GO:0051897 9.88 FGFR1 KIT PDGFRA PDGFRB
3 phosphatidylinositol phosphorylation GO:0046854 9.87 FGFR1 KIT PDGFRA PDGFRB
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.86 FLT3 KIT PDGFRA PDGFRB
5 cell migration GO:0016477 9.85 FGFR1 PDGFRA PDGFRB
6 regulation of cell proliferation GO:0042127 9.85 ABL1 FGFR1 KIT
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.85 ABL1 JAK2 PDGFRA
8 positive regulation of MAPK cascade GO:0043410 9.85 FGFR1 FLT3 KIT PDGFRA PDGFRB
9 male gonad development GO:0008584 9.82 KIT PDGFRB WT1
10 cell chemotaxis GO:0060326 9.82 KIT PDGFRA PDGFRB
11 positive regulation of MAP kinase activity GO:0043406 9.81 FGFR1 FLT3 KIT PDGFRB
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 FLT3 JAK2 KIT
13 MAPK cascade GO:0000165 9.8 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
14 phosphatidylinositol-mediated signaling GO:0048015 9.77 FGFR1 PDGFRA PDGFRB
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.77 ABL1 FLT3 KIT PDGFRA PDGFRB
16 platelet-derived growth factor receptor signaling pathway GO:0048008 9.73 ABL1 JAK2 PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.71 FLT3 KIT PDGFRA PDGFRB
18 cell differentiation GO:0030154 9.7 ABL1 FLT3 JAK2
19 peptidyl-tyrosine phosphorylation GO:0018108 9.7 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
20 adrenal gland development GO:0030325 9.67 PDGFRA WT1
21 cardiac myofibril assembly GO:0055003 9.67 PDGFRA PDGFRB
22 male genitalia development GO:0030539 9.66 PDGFRA WT1
23 regulation of actin cytoskeleton reorganization GO:2000249 9.66 ABL1 PDGFRA
24 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.65 JAK2 PDGFRB
25 negative regulation of cell-cell adhesion GO:0022408 9.65 ABL1 JAK2
26 metanephric mesenchyme development GO:0072075 9.64 PDGFRB WT1
27 retina vasculature development in camera-type eye GO:0061298 9.63 PDGFRA PDGFRB
28 myeloid progenitor cell differentiation GO:0002318 9.62 FLT3 KIT
29 metanephric S-shaped body morphogenesis GO:0072284 9.61 PDGFRB WT1
30 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.61 ABL1 PDGFRB
31 metanephric glomerular capillary formation GO:0072277 9.59 PDGFRA PDGFRB
32 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.58 PDGFRA PDGFRB
33 positive regulation of phospholipase C activity GO:0010863 9.56 FGFR1 KIT PDGFRA PDGFRB
34 negative regulation of apoptotic process GO:0043066 9.55 PDGFRB WT1
35 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
36 protein autophosphorylation GO:0046777 9.17 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
37 phosphorylation GO:0016310 10.04 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
38 protein phosphorylation GO:0006468 10.02 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
39 positive regulation of cell proliferation GO:0008284 10.01 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB

Molecular functions related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.98 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
2 kinase activity GO:0016301 9.87 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
3 nucleotide binding GO:0000166 9.85 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
4 protein kinase activity GO:0004672 9.8 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.71 FGFR1 KIT PDGFRA PDGFRB
6 SH2 domain binding GO:0042169 9.56 ABL1 JAK2
7 phosphatidylinositol 3-kinase binding GO:0043548 9.55 JAK2 PDGFRB
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.55 FGFR1 FLT3 KIT PDGFRA PDGFRB
9 platelet-derived growth factor receptor binding GO:0005161 9.52 PDGFRA PDGFRB
10 platelet-derived growth factor binding GO:0048407 9.51 PDGFRA PDGFRB
11 vascular endothelial growth factor-activated receptor activity GO:0005021 9.49 FLT3 PDGFRA
12 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRA PDGFRB
13 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 FGFR1 FLT3 JAK2 KIT PDGFRA PDGFRB
14 protein tyrosine kinase activity GO:0004713 9.17 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
15 protein binding GO:0005515 10.28 ABL1 CDK5RAP2 FGFR1 FIP1L1 FLT3 JAK2
16 transferase activity GO:0016740 10.02 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA

Sources for Chronic Eosinophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....